PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400999
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1400999
Mast Cell Tumors Treatment Market size was valued at USD 5,100 Million in 2022, expanding at a CAGR of 3.6% from 2023 to 2030.
Mast cell tumors (MCTs) are a kind of cancer that is frequent in dogs. Mast cells, a kind of immune cell implicated in allergic responses and inflammation, are the source of these tumors. MCTs come in a variety of sizes, shapes, and malignancies. Mast cell tumors are normally treated surgically, with the goal of entirely excising the tumor. Additional treatments, such as radiation, chemotherapy, or targeted drugs, may be required in certain circumstances, particularly for aggressive or metastatic tumors. Regular veterinarian check-ups and monitoring are essential for dogs at risk of MCTs since early discovery and timely treatment are critical for a favorable outcome.
Mast Cell Tumors Treatment Market- Market Dynamics
Increasing emphasis on precision medicine in veterinary oncology propel market demand
Targeted therapy becomes increasingly possible as knowledge of the genetic and molecular mechanisms that contribute to MCT genesis and progression improves. This personalized method tailor's medicines to the tumor's individual features, maximizing effectiveness while minimizing negative effects. The development of innovative targeted medications and immunotherapies is gaining traction, led by genetic and molecular analysis of individual tumours. This driver improves not just treatment results but also the entire quality of life for dogs suffering from MCTs and other malignancies.
Mast Cell Tumors Treatment Market- Key Insights
As per the analysis shared by our research analyst, the global Mast Cell Tumors Treatment market is estimated to grow annually at a CAGR of around 3.6% over the forecast period (2023-2030)
The Mast Cell Tumors Treatment industry is projected to grow at a significant rate due to increasing emphasis on precision medicine in veterinary oncology.
Based on Drug Class segmentation, Epinephrine was predicted to show maximum market share in the year 2022
Based on Route of Administration segmentation, Injectables was the leading Drug Class in 2022
On the basis of region, Asia Pacific was the leading revenue generator in 2022
The Global Mast Cell Tumors Treatment Market is segmented on the basis of Drug Class, Route of Administration, Distribution Channel, and Region.
The market is divided into four categories based on Drug Class: Antihistamines, Epinephrine, Steroids, Mast-cell stabilizers. The Epinephrine dominates the market. Because MCTs have the ability to produce histamines, which may cause severe allergic responses in certain circumstances, epinephrine need may occur during therapy. As an emergency medication, epinephrine aids in the management of anaphylactic responses caused by MCT degranulation, allowing for faster intervention and better patient outcomes.
The market is divided into three categories based on Route of Administration: Oral, Injectables, Topical. The Injectables sector dominates the market and is likely to maintain its dominance during the forecast period. Injectable medicines are in high demand for the treatment of mast cell tumors for a variety of reasons. They are used to deliver chemotherapy, targeted treatments, and emergency medications like as epinephrine in situations of severe allergic responses induced by MCT degranulation, providing successful and speedy treatment of this difficult type of cancer.
Mast Cell Tumors Treatment Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Mast cell tumors (MCTs) in dogs are becoming more popular in the Asia-Pacific area. This tendency is influenced by a variety of things. Increased pet ownership rates in several nations around the area have resulted in a burgeoning market for veterinarian services and treatments. Second, increased knowledge of canine health issues, particularly cancers such as MCTs, has prompted more pet owners to seek medical attention for their pets. Finally, advances in veterinary oncology and an increasing number of specialized veterinary clinics and hospitals in the Asia-Pacific area have enhanced access to diagnostic and treatment choices, satisfying the region's growing need for effective MCT treatments.
The therapy landscape for mast cell tumors (MCTs) is dynamic, with various elements at work. Chemotherapy and targeted medicines are available from leading veterinary pharmaceutical firms such as Zoetis, Elanco, and Merck Animal Health. Furthermore, sophisticated radiation therapy are available at specialized veterinary cancer centers such as PetCure cancer. Research and development initiatives targeted at developing novel medicines can have an impact on the environment. Collaboration among pharmaceutical firms, research institutions, and veterinary clinics promotes MCT therapy advancement. With a rising focus on pet healthcare, competition promotes therapeutic improvements, eventually helping canine MCT sufferers and their families.
In May 2023, Sensus Healthcare Inc., a leading provider of sophisticated medical devices for non-surgical skin cancer and keloid scar treatment, is pleased to announce that their superficial radiation therapy SRT-100 system has shown encouraging results in treating Cutaneous Mast Cell Tumours (MCTs) in cats. This new restricted research, which recently appeared in the Journal of the American Veterinary Medical Association, shows the potential efficacy and safety of SRT therapy.
The scope of this report covers the market by its major segments, which include as follows: